RBC Reiterates Outperform Rating on Ariad (ARIA)

September 6, 2013 2:45 PM EDT Send to a Friend
Get Alerts ARIA Hot Sheet
Price: $5.79 -0.17%

Rating Summary:
    10 Buy, 12 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 14 | New: 40
Trade ARIA Now!
Join SI Premium – FREE
RBC Capital today maintained an Outperform rating on Ariad Pharmaceuticals (NASDAQ: ARIA) with a price target of $28.00. Analyst Michael Yee sees a number of catalysts going forward, including strong front-line Iclusig data presented at the American Society of Hematology meeting in December.

Separately, investors note that Ariad will present at the Morgan Stanley Global Healthcare in New York and Stifel Healthcare Conference in Boston next week.

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $20.75 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Morgan Stanley, RBC Capital

Add Your Comment